Abstract
The aim of this study was to describe the off-label conditions of use for levosimendan in the paediatric population of a tertiary referral hospital. This is a retrospective observational study conducted between January 2007 and January 2014. Inclusion criteria were as follows: 100 % of paediatric patients who received intravenous perfusions of levosimendan during the study period. The following data were gathered: age, sex, diagnosis, dose administered, duration and date of the perfusion, number of perfusions per patient, previous inotropic and concomitant treatment, side effects and survival. A total of 32 patients were included in the study (56 % male). The mean age at the moment of administration was 4 months (range 2 days–15 years). During the study period, a total of 70 infusions were recorded. Fifteen of the 32 patients (46.9 %) received repeat doses, with a mean interval between doses of 8 days (range 3–37 days). The doses used were between 0.05 and 0.2 mcg/kg/min. Loading doses were not used in any cases. At the moment of receiving the infusion, all of the patients were receiving conventional treatment without any response, including inotropic support in 88 % of the cases. The administration of levosimendan was only suspended in one case due to the appearance of severe hypotension. In the rest of the administrations, it was well tolerated, without registering any severe side effect during the infusion process. Levosimendan proved to be a safe, effective strategy in our paediatric population. The good tolerance observed may be related to the absence of an initial bolus or loading dose.
Similar content being viewed by others
References
Angadi U, Westrope C, Chowdhry MF (2013) Is levosimendan effective in paediatric heart failure and post-cardiac surgeries? Interact Cardiovasc Thorac Surg 17(4):710–714
Fernández de Palencia-Espinosa MA, Cárceles-Barón MD, Blázquez-Álvarez MJ, Arocas-Casañ V, de la Rubia-Nieto A (2012) Retrospective descriptive study about the use of levosimendan in children undergoing surgical correction for congenital heart disease. Rev Esp Anestesiol Reanim 59(9):489–496
Garisto C, Favia I, Ricci Z, Chiara LD, Morelli S, Giorni C, Vitale V, Picardo S, Di Donato RM (2010) Initial singlecenter experience with levosimendan infusion for periopertive management of univentricular heart with ductal dependent systemic circulation. World J Pediatr Congenit Heart Surg 1(3):292–299
Magliola R, Moreno G, Vassallo JC, Landry LM, Althabe M, Balestrini M et al (2009) Levosimendan, a new inotropic drug: experience in children with acute heart failure. Arch Argent Pediatr 107:139–145
Osthaus WA, Boethig D, Winterhalter M, Huber D, Goerler H, Sasse M, Sümpelmann R (2009) First experiences with intraoperative Levosimendan in pediatric cardiac surgery. Eur J Pediatr 168(6):735–740
Ricci Z, Garisto C, Favia I, Vitale V, Di Chiara L, Cogo PE (2012) Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial. Intensive Care Med 38(7):1198–1204
Suominen PK (2011) Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure. BMC Anesthesiol 11:18
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vilaboa Pedrosa, C., Martínez Roca, C., Yáñez Gómez, P. et al. Experience with Levosimendan in 32 Paediatric Patients. Pediatr Cardiol 36, 1038–1041 (2015). https://doi.org/10.1007/s00246-015-1117-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-015-1117-5